Matthew Davids, MD from Dana-Farber Cancer Institute, Boston, MA outlines the differences in the treatment of older and younger patients. In older patients monotherapy with kinase inhibitors and venetoclax may be a suitable option. In younger patients doctors may have more ambitious goals, curing these patients or at least getting them into complete remission (CR). Multiple strategies could be explored either with combining novel agents with traditional chemoimmunotherapy, or using only a combination of novel agents. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Author: Editor
Owen O’Connor, MD, PhD from Columbia University Medical Center, New York, NY discusses his colleague Dr George Tangs investigation into the PI3 kinases, with the aim of understanding why TGR-1202 is different from idelalisib and duvelisib. His work has reinforced the knowledge of TGR-1202s chemical structure and the effect it has on protein translation, specifically MIC protein. Dr OConnor also discusses the Phase II UNITY trial (NCT02793583) that aims to assess the efficacy and safety of Ublituximab + TGR-1202 and TGR-1202 monotherapy in patients previously treated for diffuse large B-cell lymphoma (DLBCL). Recorded at the European Hematology Association (EHA) 2016…
Matthew Davids, MD from Dana-Farber Cancer Institute, Boston, MA outlines the poster demonstrating preliminary results from an investigator initiated study looking at the BTK inhibitor ibrutinib given in combination with FCR chemotherapy as a first line therapy in patients 65 years or younger. Results have shown very good tolerability and good levels of minimal residual disease (MRD) negativity. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Owen O’Connor, MD, PhD from Columbia University Medical Center, New York, NY outlines his presentation on the updates from the Phase I clinical trial examining ublituximab in combination with TGR-1202 for non-Hodgkin lymphoma (NCT02006485). Current results confirmed that the drug is well-tolerated and has a highly-favourable safety profile and a continued demonstration of good efficacy in patients with indolent lymphoma, as well as patients with diffuse large B-cell lymphoma (DLBCL). Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark
Davide Rossi, MD, PhD from University of Eastern Piedmont, Vercelli, Italy outlines the novel treatment options for chronic lymphocytic leukemia (CLL) patients. Due to the vast number of these new treatments doctors need to have tools to help them tailor treatments to the patient. Consequently there is a growing need to develop prognostic and predictive factors that may help in the customization of treatment. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Matthew Davids, MD, from Dana-Farber Cancer Institute, Boston, MA outlines the importance of being aware of a patient’s tumor lysis risk status in chronic lymphocytic leukemia (CLL). This status can be determined by the the size of their lymph nodes and the height of their lymphocytosis. Dr Davids continues on to emphasize the importance starting venetoclax treatment at a low dose and ramping the dosage up week by week. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Matthew Davids, MD from Dana-Farber Cancer Institute, Boston, MA outlines the poster demonstrating the safety analysis of venetoclax, BCL-2 inhibitor, which has been approved for relapsed/refractory chronic lymphocytic leukemia (CLL) 17p patients. The analysis of 300 patients showed no new safety signals, only a small risk of laboratory tumor lysis syndrome, neutropenia and gastrointestinal toxicities. Dr Davids further discusses how patients on venetoclax show tolerance to the drug for long periods of time. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Anton Hagenbeek, MD, PhD from the University of Amsterdam, Amsterdam, Netherlands discusses how he hopes the treatment of cancer will progress in future. Prof. Hagenbeek hopes for intelligent combinations of targeted agents and a move towards personalized medicine. He further argues for conducting small Phase II trials in order to speed up the process of drug approval, meaning that drugs could become available at faster rates. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Anton Hagenbeek, MD, PhD from the University of Amsterdam, Amsterdam, Netherlands talks about the issue of drug costs in oncology. Drug combinations are effective but particulalry costly according to Prof. Hagenbeek. He argues that there is an urgent need to talk to the biotech companies producing the drugs and to agree on transparent pricing of these drugs and socially acceptable profit margins. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Anton Hagenbeek, MD, PhD from the University of Amsterdam, Amsterdam, Netherlands discusses how he hopes the treatment of cancer will progress in future. Prof. Hagenbeek hopes for intelligent combinations of targeted agents and a move towards personalized medicine. He further argues for conducting small Phase II trials in order to speed up the process of drug approval, meaning that drugs could become available at faster rates. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark
Immunotherapy is a groundbreaking therapy for solid tumors. Where are we with using immunotherapy to treat multiple myeloma? Myeloma expert Dr. Jatin Shah of MD Anderson Cancer Center responds with cutting edge information about the current state of immunotherapy. Listen as Dr. Shah discusses exciting news on checkpoint inhibitors and CAR-T cell data for patients living with multiple myeloma. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Should patients consider participating in a clinical trial? Andrew Schorr, Patient Power founder and host, leads a discussion with advanced prostate experts, Dr. William Catalona and Dr. Russell Szmulewitz as they explore various approaches to deciding if a clinical trial is right for you. Drs. Catalona and Szmulewitz work to break down the barriers to understanding why and how clinical trials work. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Should patients consider participating in a clinical trial? Andrew Schorr, Patient Power founder and host, leads a discussion with advanced prostate experts, Dr. William Catalona and Dr. Russell Szmulewitz as they explore various approaches to deciding if a clinical trial is right for you. Drs. Catalona and Szmulewitz work to break down the barriers to understanding why and how clinical trials work. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Eduardo Rego, MD, PhD from University of São Paulo, Brazil discusses coagulopathy in acute myeloid leukemia (AML) at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. There are several new features that are now known, such as the presence of microparticles derived from self-fragments of leukemia cells as well as healthy cells. These microparticles have a very high expression of tissue factor (TF). TF plays an important role in coagulation. Experimental studies on annexin II which is a surface receptor that binds to plasminogen and TPA, have shown a subsequent increases in plasmin generation. This knowledge has…
Eduardo Rego, MD, PhD from University of São Paulo, Brazil discusses the main challenges, primarily bleeding, practitioners face when treating acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML). Most patients present severe bleeding, primarily intracranial bleeding. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Eduardo Rego, MD, PhD from University of São Paulo, Brazil outlines his presentation on his experience with networking as a way of improving the assistance and results of patients with acute leukemia in developing countries. With the support of the American Society of Hematology (ASH) the International Consortium on Acute Promyelocytic Leukemia (IC-APL) was established to reduce the gap between developed and developing countries.The structure is based on networking and includes providing medical education to the community, as well as providing fast and efficient methods of diagnostics. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Eduardo Rego, MD, PhD from University of São Paulo, Brazil outlines his presentation on his experience with networking as a way of improving the assistance and results of patients with acute leukemia in developing countries. With the support of the American Society of Hematology (ASH) the International Consortium on Acute Promyelocytic Leukemia (IC-APL) was established to reduce the gap between developed and developing countries. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany outlines the format of the annual workshop of the German CLL Study Group (GCLLSG) where physicians and researchers present the results of clinical trials and discuss problems. According to Dr Eichhorst there are open and closed sessions, where open sessions are free for the public to participate in while closed sessions are only for experts. In these closed sessions, ongoing and upcoming trials are discussed. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Jean-Jacques Kiladjian, MD, PhD from Saint-Louis Hospital & Paris Diderot University, Paris, France discusses the impact of patients registries on research and the patient community. Dr Kiladjian gives the example of Dr Martin Griesshammer, MD, PhD who presented data from a patient registry of pregnant women with polycythemia vera (PV), with the data consequently helping in the management of pregnancy in these patients. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Jean-Jacques Kiladjian, MD, PhD from Saint-Louis Hospital & Paris Diderot University, Paris, France discusses a selection of topics covered during the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Dr Kiladjian outlines presentations on myeloproliferative neoplasms, specifically essential thrombocythemia (ET) and the PT-1 trial, and polycythemia vera (PV). In talks regarding treatment of PV it was discussed how ruxolitinib could lessen the JAK2 mutant allele burden.
Significant advances have elevated breast cancer care to new levels of success and complexity. One such advance has been the availability of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in women with estrogen receptor-positive (ER+) metastatic breast cancer (MBC). This webcast consists of the faculty presentations from a satellite symposium held June 4, 2016 at the annual oncology meeting that explored the current and expanding pool of information about these agents, as well as best practices for their current and potential use in MBC. In this presentation, Dr. Maura N. Dickler discusses the ongoing investigations and future applications of…
Significant advances have elevated breast cancer care to new levels of success and complexity. One such advance has been the availability of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in women with estrogen receptor-positive (ER+) metastatic breast cancer (MBC). This webcast consists of the faculty presentations from a satellite symposium held June 4, 2016 at the annual oncology meeting that explored the current and expanding pool of information about these agents, as well as best practices for their current and potential use in MBC. In this presentation, Dr. Nicholas C. Turner discusses the current clinical data for the use…
Significant advances have elevated breast cancer care to new levels of success and complexity. One such advance has been the availability of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in women with estrogen receptor-positive (ER+) metastatic breast cancer (MBC). This webcast consists of the faculty presentations from a satellite symposium held June 4, 2016 at the annual oncology meeting that explored the current and expanding pool of information about these agents, as well as best practices for their current and potential use in MBC. In this presentation, Dr. Harold J. Burstein discusses the mechanistic activity and development history of…
Significant advances have elevated breast cancer care to new levels of success and complexity. One such advance has been the availability of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in women with estrogen receptor-positive (ER+) metastatic breast cancer (MBC). Please join expert faculty discussing highlights of a satellite symposium held June 4, 2016 at the annual oncology meeting that explores the current and expanding pool of information about these agents, as well as best practices for their current and potential use in MBC.
Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY discusses the results of a Phase III trial of bendamustine and rituximab plus placebo vs bendamustine and rituximab plus idelalisib (NCT01569295). The primary endpoint was progression-free survival (PFS), which was favorable to adding idealisib. There was also an overall survival (OS) advantage to adding idealisib. Dr Zelenetz further discusses the side effects of this drug combination. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.
Irene Ghobrial, MD of the Dana-Farber Cancer Institute (DFCI), discusses progression of multiple myeloma (MM), which comes from conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. It is not know, however, which patients will progress. Improving our understanding of the development of the disease means that we could be treating patients earlier and avoiding the progression into advanced multiple myeloma and the associated complications, such as organ damage. Current biomarkers cannot be used to predict with accuracy the progression of the disease, so we need better tools, such as next-generation sequencing (NGS) and molecular biomarkers.…
Howard Burris, MD from Sarah Cannon, Nashville, TN discusses the use and benefits of liquid biopsies, which include being less invasive, more timely and easier to obtain. Dr Burris further discusses whether liquid biospies will eliminate the need to do solid tumor biopsies and argues that both will have a place in clinical practice. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.
Howard Burris, MD from Sarah Cannon, Nashville, TN discusses TGR-1202 for chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL). TGR-1202 is a PI3K delta inhibitor and Dr Burris discusses how it may be the third compound in this area that will be used in the clinic next to idelalisib and IPI-145. TGR-1202 is well tolerated and is used as a single agent and in combination. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.
Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY discusses the results of a Phase III trial of bendamustine and rituximab plus placebo vs bendamustine and rituximab plus idelalisib (NCT01569295). The primary endpoint was progression-free survival (PFS), which was favorable to adding idealisib. There was also an overall survival (OS) advantage to adding idealisib. Dr Zelenetz further discusses the side effects of this drug combination. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.
Charles Craddock, CBE, FRCP, FRCPath, DPhil, from Queen Elizabeth Hospital, Birmingham, UK explains how the definition of elderly is less dependent on chronological age but instead biological age in acute myeloid leukemia (AML). Consequently this implies that intense chemotherapy and transplants may be suitable in fit patients up to the age of 70, whereas in younger patients with co-morbidities treatment is associated with greater risks. However molecular complexities is significantly greater in old patients with AML thus there is a higher risk of relapse after intensive chemotherapy, therefore treatment strategies must be tailored. Prof Craddock also discusses the important role…
Jae Park, MD from Memorial Sloan Kettering Cancer Center, New York, NY discusses current research in acute lymphoblastic leukemia (ALL). Dr Park first discusses a Phase III TOWER study which investigated blinatumomab vs standard of care (NCT02013167), with results showing blinatumomab performing better than conventional therapy. Then Dr Park continued to discuss a second trial on inotuzaumab, which also is compared to a standard of care arm. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Jacqueline Barrientos, MD from Northwell Health, New York, NY discusses drug treatment options for chronic lymphocytic leukemia (CLL), specifically ibrutinib, idelalisib and venetoclax. Current research on these drugs looks promising however side-effects that have not been seen before are arising. In studies with ibrutinib the data is showing higher incidence of minimal residual disease (MRD) negativity over time. Idelalisib research is demonstrating that frontline patients chance of developing an autoimmune complication or infection is very high. Consequently in Europe idelalisib is not recommended for frontline patients and clinical trials for frontline patients have been ceased. Finally venetoclax studies have stressed…
Jacqueline Barrientos, MD from Northwell Health, New York, NY discuss a placebo-controlled study of idelalisib in combination with bendamustine plus rituximab, also known as BR (NCT01569295). The results after a longer follow-up showed a median progression free survival (PFS) of 23 months while patients with 17p deletions had a PFS of 16 months. Dr Barrientos continues to discuss why this difference in PFS may have arisen, either because of a higher rate of discontinuation of therapy in 17p del patients due to side effects or due to chromosome instability leading to resistance. Recorded at the European Hematology Association (EHA) 2016…
Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses the unmet medical need of patients with polycythemia vera (PV) and essential thrombocythemia (ET), by outlining her arguments for new treatment options. Currently, all treatment guidelines are based on the risk of thrombosis. If the patient is low-risk based on age or history of thrombosis, they receive phlebotomy or low dose aspirin. If they are high risk they will receive high-dose aspirin and hydroxyurea, or a second line of treatment of interferon alpha. However even with these treatments thrombotic events still occur, highlighting how these drug are ineffective. Furthermore,…
Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses Momelotinib at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Momelotinib is a JAK 1 and JAK 2 inhibitor and even though only data from the Phase I and Phase II trial is available, there has been positive results similar to ruxolitinib. Momelotinib has shown to have an essentially positive impact with patients with anemia and transfusion dependency. This differing result to ruxolitinib is thought to be due to momelotinibs inhibition of the hepcidin production pathway in hepatocytes. However, momelotinib has a specific side-effect, peripheral neuropathy,…
Bruno Paiva, PhD from the University of Navarra, Pamplona, Spain outlines his presentation on the role of minimal residual disease (MRD) in multiple myeloma, specifically its role as a prognostic factor and in the future as biomarker to aid in treatment decisions. Dr Paiva, outlines the importance of studying the biology of tumor resistant clones at the MRD level. The first reason discussed is to understand the mechanisms of ultra-chemoresistance in order to develop novel targets and therapy combinations. The second is to understand the biology and genetic features of the MRD cell. Recorded at the European Hematology Association (EHA)…
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany outlines tumor lysis syndrome as a side-effect of venetoclax in treatment of patients with chronic lymphocytic leukemia (CLL). Tumor lysis syndrome can be avoided if the initial dosage begins at 20mg and is doubled every week till a dosage of 400mg is reached. Certain patients have a particularly high risk of developing tumor lysis, especially those with a high lymphoma burden, high lymphocyte count or large lymph nodes (above 10cm). These patients may have to come more frequently or stay for extended periods of time in the clinic. Recorded at the…
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany outlines current clinical research in chronic lymphocytic leukemia (CLL). Dr Eichhorst discusses the recruitment of patients in the CLL14 trial which is testing efficacy and safety of obinutuzumab plus venetoclax versus obinutuzumab plus chlorambucil (NCT02242942). She then continues to discuss the upcoming results from the Phase II CLL2-GiVe trial which involved an induction treatment of bendamustine followed by maintenance treatment of ibrutinib or venetoclax in combination with obinutuzumab (NCT02758665). Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discusses the economic burden of treating chronic lymphocytic leukemia (CLL). A solution Dr Eichhorst proposes is raising the price of treatment in the beginning, but ensuring that this treatment eradicates the disease. Consequently the patient does not have to pay for continuous treatment. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discusses using venetoclax in the treatment of patients with chronic lymphocytic leukemia (CLL). Venetoclax will be approved for high risk CLL patients with 17p deletions, and has received good results in studies. Furthermore it has performed well in contrast with ibrutinib or idelalisib, as complete responses (CR) and minimal residual disease (MRD) negativity in relapsed/refractory CLL has been reported – even in monotherapy. Dr Eichhorst also discusses combinations with the CD20 antibody. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discusses updates in current clinical trials being undertaken in the field of chronic lymphocytic leukemia (CLL). Treatment of patients with 17p deletions have shown very good response rates, with a median progression-free survival of 13 months. Dr Eichhorst also discusses the HELIOS Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory CLL (EudraCT No. 2012-000600-150). The bendamustine and rituximab plus ibrutinib arm of this study has shown continuous improvement in the response quality and minimal residual negativity (MRD). Recorded at the European Hematology Association (EHA) 2016 Annual…
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discusses the treatment of elderly CLL patients. In the beginning of treatment a geriatric assessment should be undertaken as well as offering support to the patient in the form of psychologists, to help the patients through the treatment phase. Prof Eichhorst also discusses ibrutinib as a treatment option for those patients who cannot tolerate CD20 antibody or who cannot travel to a hematologist and consequently an oral drug would be beneficial. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discussing treatment options for co-morbid chronic lymphocytic leukemia (CLL) patients. These individuals face frequent medical problems which have to be taken into consideration when choosing a treatment regimen. Dosage reduced treatment should be considered as an option, for example fludareabine plus cyclophosphamide plus rituximab. Another combination that has shown promising responses is bendamustine plus rituximab. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Are any immunotherapy approaches currently available to treat advanced prostate cancer patients? Andrew Schorr, Patient Power Founder and Host, leads a discussion with experts Dr. William Catalona and Dr. Russell Szmulewitz. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses momelotinib at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Momelotinib is a JAK 1 and JAK 2 inhibitor and even though only data from the Phase I and Phase II trial is available, there has been positive results similar to ruxolitinib. Momelotinib has shown to have an essentially positive impact with patients with anemia and transfusion dependency. This differing result to ruxolitinib is thought to be due to momelotinibs inhibition of the hepcidin production pathway in hepatocytes. However, momelotinib has a specific side-effect, peripheral neuropathy,…
Robin Foà , MD from the Sapienza University, Rome, Italy gives an overview of the session on ‘Biosimilars: shaping the future of Hematology’ held at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Prof. Foà discusses how advancements in therapy are impacting on the prognosis of various cancers and, in this context, the problems associated with an aging society. He then talks about drug costs and the issue of access to novel drugs. According to Prof. Foà , biosimilars may help reduce costs and increase access to drugs.
Klaus Okkenhaug, PhD from Babraham Institute, Cambridge, UK discusses alternative options for the treatment for chronic lymphocytic leukemia (CLL). Similar to idelalisib are the SYK inhibitors which are awaiting approval. There are also BTK inhibitors, such as ibrutinib.Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Mohamad Mohty, MD, PhD from Saint-Antoine Hospital, Paris, France discusses the current progress being made in multiple myeloma (MM) research. In frontline patients eligible for transplant, practitioners should aim to deepen the response rate and target minimal residual disease (MRD) before transplant. Prof Mohty suggests that second generation proteasome inhibitors are extremely potent in this setting and will be further strengthened by the addition of a monoclonal antibody, such as daratumumab, to achieve negative MRD status. In the transplant setting, current research is showing the importance of maintenance therapy. The meta analysis of three large randomised trials has shown an…
Jae Park, MD from Memorial Sloan Kettering Cancer Center, New York, NY discusses the efficacy and safety of the CD19 targeted chimeric antigen receptor (CAR) T-cells in relapsed B-cell acute lymphoblastic leukemia (ALL) adult patients. CAR T-cells are the patient’s own T-cells which have been genetically engineered to express a chimeric antigen receptors that’s engineered to target a specific tumour antigens, in this case CD19. A phase I clinical trial has been conducted on 51 subjects, and has had positive results. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.